Bayer revised guidance due to the announced Diabetes business divestment. In Q2, sales rose strongly (+18% to €12,090m; organic: +4%) but organically CropScience and MaterialScience did not make the pace. The gross profit margin clearly improved (56.1% after 51.2%), helped by the positive FX developments and lower raw material prices as well as higher volumes at MaterialScience. EBITDA jumped +24% to €2,648m and net profit attributable to shareholders rose strongly up by +21% to &eu
29 Jul 2015
Guidance adjustment was not caused by performance
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Guidance adjustment was not caused by performance
Bayer AG (BAYN:WBO) | 0 0 0.5% | Mkt Cap: 80,975m
- Published:
29 Jul 2015 -
Author:
Martin Schnee -
Pages:
3
Bayer revised guidance due to the announced Diabetes business divestment. In Q2, sales rose strongly (+18% to €12,090m; organic: +4%) but organically CropScience and MaterialScience did not make the pace. The gross profit margin clearly improved (56.1% after 51.2%), helped by the positive FX developments and lower raw material prices as well as higher volumes at MaterialScience. EBITDA jumped +24% to €2,648m and net profit attributable to shareholders rose strongly up by +21% to &eu